Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients

The pharmacokinetics and therapeutic effects of bezafibrate were studied in 15 RDT patients in a placebo controlled trial. Serum half life of bezafibrate was prolonged to 17--21.5 hours compared to 1.6--2.1 hours in normals. Adequate dosage in RDT patients was found to be 200mg every 3rd day. Bezafibrate treatment resulted in significant decrease in the serum concentrations of triglycerides, total cholesterol and LDL-cholesterol, whereas HDL-cholesterol serum levels increased. Under this dosage regimen no adverse side effects were observed. Bezafibrate offers the possibility of correcting disturbances of lipid metabolism of RDT patients, possibly involved in the pathogenesis of atherosclerosis of these patients.